Breaking News
Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy.
The U.S. Food and Drug Administration has granted accelerated approval for Novartis’ Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
The U.S. Food and Drug Administration (FDA) has approved a new type of antibiotic to treat urinary tract infections (UTIs).
BioTrending
- By Trudie Mitschang
When it comes to online health information, the Internet is a place where falsehoods flourish. Combating questionable content is no easy task, requiring education, legislation and diligence from stakeholders in the healthcare, scientific and public health communities.
- By Meredith Whitmore
Your words, tone and body language can escalate patient fears, but they also have the power to ease anxiety and help patients cope.
- By Jim Trageser
Though mostly eradicated in the U.S., treatment for rabies must begin immediately with hyperimmune globulin and vaccines.
- By Keith Berman, MPH, MBA
With 16 FVIII products now approved for the treatment of hemophilia A, many patients with this disease are now able to live a normal life.
BSTQ Podcast: Marketplace News & Insights
Awards
BSTQ is an Industry Award-Winning Journal
Since its debut in 2009, BioSupply Trends Quarterly’s articles have been recognized by some of the industry’s most prominent organizations, earning platinum and gold awards.
